Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Anagrelide may cause a range of side effects during use.What side effects may Anagrelide cause?Inform your doctor promptly if you experience any of the following symptoms that are ···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：39
Anagrelide is used to reduce the platelet count in patients with myeloproliferative disorders (platelets are blood cells required for controlling bleeding).What is Anagrelide?Patie···【more】
Article source：Captain MedicineRelease date：2026-01-30Recommended：39
Revumenib (Revuforj) is an oral, first-in-class targeted Menin protein inhibitor indicated for the treatment of relapsed or refractory acute leukemia with specific genetic abnormal···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：67
Revumenib (trade name: Revuforj) is an oral, first-in-class targeted Menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene rearrangem···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：67
Revumenib (trade name: Revuforj) is an oral targeted drug of the Menin inhibitor class, indicated for the treatment of relapsed or refractory acute leukemia with KMT2A gene rearran···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：61
Revuforj carries a risk of differentiation syndrome, and patients and their family members should be alert to relevant symptoms during treatment.Precautions for Revuforj Administra···【more】
Article source：Captain MedicineRelease date：2026-01-29Recommended：65
Rivimeinib is available in three tablet strengths: 25 mg, 110 mg, and 160 mg.What are the side effects of Rivimeinib (Revuforj)?The most common side effects of Revuforj include ble···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：57
Combination of this class of drugs with Revuforj is not recommended; if co-administration is unavoidable, healthcare providers will need to monitor you more frequently for QTc inte···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：58
Remission is the primary treatment goal for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).How effective is Revuforj for treatment?Approximately one in five pa···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：61
Administration of rivoceranib is continued until disease progression, occurrence of intolerable toxicity, failure to achieve morphologic leukemia-free state after 4 cycles of treat···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：63
The recommended dosage of Revuforj varies according to the patient's body weight and concomitant use of strong CYP3A4 inhibitors.Administration of RevuforjFor patients aged 1 y···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：59
Take Revuforj exactly as directed by your healthcare provider. Do not change your dose or stop taking Revuforj unless your healthcare provider tells you to do so.What is the recomm···【more】
Article source：Captain MedicineRelease date：2026-01-28Recommended：68
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：1592025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：3992024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：1732025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：1532025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：1682025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：1642025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
